Exploratory Biomarker Analysis Of Trastuzumab Deruxtecan In Destiny-Gastric01, A Randomized, Phase 2, Multicenter, Open-Label Study In Patients With Her2-Positive Or -Low Advanced Gastric Or Gastroesophageal Junction Adenocarcinoma

ANNALS OF ONCOLOGY(2021)

引用 8|浏览5
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要